POU5F1/Oct-4 expression in breast cancer tissue is significantly associated with non-sentinel lymph node metastasis

BackgroundAt present, few studies have explored the significance of POU5F1 (also known as octamer-bingding factor, Oct-4 or Oct-3) expression in breast cancer tissues.MethodsA total of 121 patients were retrospectively selected between May 2010 and March 2013 to investigate the relationship between POU5F1/Oct-4 expression in breast cancer tissues and non-sentinel lymph node (non-SLN) metastases and to validate the Memorial Sloan-Kettering Cancer Center (MSKCC) nomogram. All patients had early-stage breast cancer, which was histologically confirmed by the Department of Surgical Oncology, The First Affiliated Hospital of China Medical University. Histological type and grade of tumors were determined from tissue samples by hematoxylin and eosin staining, while the presence of POU5F1/Oct-4 protein was determined by immunohistochemistry. POU5F1/Oct-4 expression levels in tissues obtained from patients with sentinel lymph node (SLN) and non-SLN metastasis and in tissues obtained from patients without lymph node metastases were compared.ResultsPOU5F1/Oct-4 expression levels in breast cancer tissues were significantly higher in both the SLN metastasis and non-SLN metastasis groups (P = 0.003 and P = 0.030, respectively). Furthermore, POU5F1/Oct-4 expression was found to be associated to both histological (P = 0.01) and molecular type (P = 0.03). Thus, our data once again confirms the validity of the MSKCC nomogram. The area under curve (AUC) was 0.919 (95 % CI: 0.869–0.969, P < 0.001). The probability of non-SLN metastasis generated from the MSKCC nomgram was significantly higher in the POU5F1/Oct-4 positive group than in the POU5F1/Oct-4 negative group. Both univariate and multivariate analysis revealed that Oct-4 expression levels were significantly associated with non-SLN metastases (P = 0.030 and P = 0.034, respectively).ConclusionsPOU5F1/Oct-4 expression levels are significantly associated with non-SLN metastases. Patients with higher probabilities of metastasis generated from the MSKCC nomogram may also have higher POU5F1/Oct-4 expression levels.

[1]  J. Miyazaki,et al.  Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells , 2000, Nature Genetics.

[2]  J. Sleeman.  The lymph node as a bridgehead in the metastatic dissemination of tumors. , 2000, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[3]  P. Lu,et al.  Clinical Implications of Stem Cell Gene Oct-4 Expression in Breast Cancer , 2011, Annals of surgery.

[4]  H. Schöler,et al.  Oct-4 transcription factor is differentially expressed in the mouse embryo during establishment of the first two extraembryonic cell lineages involved in implantation. , 1994, Developmental biology.

[5]  P. Tan,et al.  Predicting the likelihood of additional lymph node metastasis in sentinel lymph node positive breast cancer: validation of the Memorial Sloan-Kettering Cancer Centre (MSKCC) nomogram , 2013, Journal of Clinical Pathology.

[6]  Michael Detmar,et al.  Tumor and lymph node lymphangiogenesis—impact on cancer metastasis , 2006, Journal of leukocyte biology.

[7]  L. Olson,et al.  Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. , 2004, Carcinogenesis.

[8]  Megan F. Cole,et al.  Core Transcriptional Regulatory Circuitry in Human Embryonic Stem Cells , 2005, Cell.

[9]  A. Bank,et al.  Preselection of transduced murine hematopoietic stem cell populations leads to increased long-term stability and expression of the human multiple drug resistance gene. , 1995, Blood.

[10]  P. Dirks,et al.  Cancer stem cells in nervous system tumors , 2004, Oncogene.

[11]  H. Schöler,et al.  Stem cell pluripotency and transcription factor Oct4 , 2002, Cell Research.

[12]  Michael W Kattan,et al.  Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Giuliano,et al.  Improved Axillary Staging of Breast Cancer with Sentinel Lymphadenectomy , 1995, Annals of surgery.

[14]  P. Goss,et al.  Examination of POU homeobox gene expression in human breast cancer cells , 1999, International journal of cancer.

[15]  H. Schöler,et al.  Oct‐4: a germline‐specific transcription factor mapping to the mouse t‐complex. , 1990, The EMBO journal.

[16]  P. Tan,et al.  Validation of a nomogram in the prediction of local recurrence risks after conserving surgery for Asian women with ductal carcinoma in situ of the breast. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

[17]  H. Schöler,et al.  Germline regulatory element of Oct-4 specific for the totipotent cycle of embryonal cells. , 1996, Development.

[18]  C. Carter,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989, Cancer.

[19]  A. Giuliano,et al.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.

[20]  T. Morikawa,et al.  Impact of CD44+CD24- cells on non-sentinel axillary lymph node metastases in sentinel node-positive breast cancer. , 2011, Oncology reports.

[21]  Hans R. Schöler,et al.  New type of POU domain in germ line-specific protein Oct-4 , 1990, Nature.

[22]  Donald E. Henson,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989 .

[23]  Peng-fei Qiu,et al.  Risk factors for sentinel lymph node metastasis and validation study of the MSKCC nomogram in breast cancer patients. , 2012, Japanese journal of clinical oncology.

[24]  D. Weaver,et al.  Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. , 1993, Surgical oncology.